MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

Search

Protagonist Therapeutics Inc

Deschisă

SectorSănătate

64.93 0.36

Rezumat

Modificarea prețului

24h

Curent

Minim

64.21

Maxim

65.27

Indicatori cheie

By Trading Economics

Venit

-23M

-35M

Vânzări

-23M

5.5M

P/E

Medie Sector

93.057

35.739

Marjă de profit

-626.956

Angajați

130

EBITDA

-23M

-42M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+11.96% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

858M

4.2B

Deschiderea anterioară

64.57

Închiderea anterioară

64.93

Sentimentul știrilor

By Acuity

50%

50%

149 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Protagonist Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 mar. 2025, 13:59 UTC

Principalele dinamici ale pieței

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

Comparație

Modificare preț

Protagonist Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

11.96% sus

Prognoză pe 12 luni

Medie 72.75 USD  11.96%

Maxim 82 USD

Minim 65 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruProtagonist Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

9

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

43.62 / 44.27Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

149 / 371 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
help-icon Live chat